Glycopyrronium bromide 흡입제(품명: 씨브리흡입용캡슐)

· Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12ed

· Martindale: The Complete Drug Reference

· 대한결핵 및 호흡기학회 COPD 진료지침 개정위원회. COPD 진료지침. 2014.

· Global Initiative for Chronic Obstructive Lung Disease(GOLD). 2016.

· Wang C, et al. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. Int J Chron Obstruct Pulmon Dis. 2015 Jan 5;10:57-68.

· Oba Y, et al. Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Ther Adv Respir Dis. 2015 Feb;9(1):3-15.

· Chapman KR, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014 Jan 17;14:4.

· Cope S, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013 Oct 7;14:100.

· Karabis A, et al. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:405-23.

· Kerwin E, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012 Nov;40(5):1106-14.

· Beeh KM. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-13.

· D'Urzo A, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011 Dec 7;12:156.

· Fogarty C, et al. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011 Mar;105(3):337-42.